Page

Name

E-mail

Message

2026-02-28

#reports #ACT

[Enact Holdings, Inc.](https://eninvs.com/all.php?name=ACT) (Insurance — Specialty) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195820)
(2026-02-03, After Market Close):

- Revenue +7.2% YoY (vs +2.0% in previous quarter and historical rate +4.2%)
- Net Income +9.9% YoY (vs +3.8% in previous quarter and historical rate +1.6%)
- Net Income margin 56.5% increased compared to 55.1% same period last year
- P/E multiple is 8.7x compared to historical level (75th percentile) of 8.3x
- P/S multiple is 5x
- Price to book: 1.1x

The company showed EPS +$4.54 per share. At the opening of the session the share price went up +6.9%

------------------------------------------------

2026-02-28

#reports #AYTU

[Aytu Biopharma](https://eninvs.com/all.php?name=AYTU) (Drug Manufacturers — Specialty and Generic) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195692)
(2025-09-23, After Market Close):

- Revenue -6.3% YoY (vs -17.6% in previous quarter and historical rate -15.0%)
- EBITDA margin -13.3% decreased compared to -12.5% same period last year
- Net Debt increased by $49 mln over the past reporting period (179.5% of market cap)
- FCF (LTM) +$0 bln (positive), 120.9% of market cap
- EV/EBITDA multiple is 45.3x compared to historical level (75th percentile) of 18x
- EV/Sales multiple is 0.7x

At the opening of the session the share price went down -12.4%

------------------------------------------------

2026-02-28

#reports #ASB

[Associated Banc-Corp](https://eninvs.com/all.php?name=ASB) (Banks — Regional) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195686)
(2026-01-22, After Market Close):

- Revenue +154.1% YoY (vs +28.7% in previous quarter and historical rate +44.2%)
- Net Income margin 44.2% increased compared to -91.8% same period last year
- P/E multiple is 12.2x compared to historical level (75th percentile) of 34.2x
- P/S multiple is 2.4x
- Price to book: 0.8x

The company showed EPS +$2.81 per share. At the opening of the session the share price went up +2.0%

------------------------------------------------

2026-02-28

#reports #AMWL

[American Well Corporation](https://eninvs.com/all.php?name=AMWL) (Health Information Services) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195677)
(2026-02-12, After Market Close):

- Revenue -22.5% YoY (vs -1.6% in previous quarter and historical rate -1.3%)
- EBITDA margin -34.5% increased compared to -67.6% same period last year
- Net Debt increased by $70 mln over the past reporting period (99.8% of market cap)
- FCF (LTM) -$0.1 bln (negative), 176.8% of market cap
- EV/EBITDA multiple is 0.6x compared to historical level (75th percentile) of 1.5x
- EV/Sales multiple is -0.4x

------------------------------------------------

2026-02-28

#reports #AIHS

[Senmiao Technology Limited](https://eninvs.com/all.php?name=AIHS) (Credit Services) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195668)
(2026-02-13, Before Market Open):

- Net Income margin -100.0% decreased compared to -50.0% same period last year
- P/S multiple is 4.3x
- Price to book: -97.2x

------------------------------------------------

2026-02-28

#reports #ACRS

[Aclaris Therapeutics](https://eninvs.com/all.php?name=ACRS) (Biotechnology) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195664)
(2026-02-26, Before Market Open):

- Revenue -94.4% YoY (vs -55.6% in previous quarter and historical rate +40.8%)
- EBITDA margin -2300.0% decreased compared to -238.9% same period last year
- Net Debt decreased by $43 mln over the past reporting period (9.2% of market cap)
- FCF (LTM) +$0 bln (positive), 1.9% of market cap
- EV/Sales multiple is 37.7x

------------------------------------------------

2026-02-28

#reports #BANR

[Banner](https://eninvs.com/all.php?name=BANR) (Banking service provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195459)
(2026-01-21, After Market Close):

- Revenue +217.4% YoY (vs +7.7% in previous quarter and historical rate +17.8%)
- Net Income margin 32.4% increased compared to -3.6% same period last year
- P/E multiple is 8.5x compared to historical level (75th percentile) of 37.9x
- P/S multiple is 2.3x
- Price to book: 1.1x

The company showed EPS +$5.67 per share. At the opening of the session the share price went down -0.7%

------------------------------------------------

2026-02-28

#reports #BANF

[BancFirst](https://eninvs.com/all.php?name=BANF) (Banking service provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195458)
(2026-01-19, Before Market Open):

- Revenue +20.8% YoY (vs +10.5% in previous quarter and historical rate -0.7%)
- Net Income +18% YoY (vs +14.3% in previous quarter and historical rate +17.0%)
- Net Income margin 46.1% decreased compared to 47.2% same period last year
- P/E multiple is 16x compared to historical level (75th percentile) of 18.8x
- P/S multiple is 7.7x
- Price to book: 2x

The company showed EPS +$7.22 per share

------------------------------------------------

2026-02-28

#reports #AIZ

[Assurant](https://eninvs.com/all.php?name=AIZ) (Insurance services provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195448)
(2026-02-10, After Market Close):

- Revenue +12.3% YoY (vs +7.0% in previous quarter and historical rate +6.0%)
- Net Income -20.2% YoY (vs +2.2% in previous quarter and historical rate +37.4%)
- Net Income margin 6.7% decreased compared to 9.5% same period last year
- P/E multiple is 11.1x compared to historical level (75th percentile) of 11.6x
- P/S multiple is 1x
- Price to book: 2.2x

------------------------------------------------

2026-02-28

#reports #AFL

[Aflac](https://eninvs.com/all.php?name=AFL) (Insurance services provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195446)
(2026-02-04, After Market Close):

- Revenue -10.5% YoY (vs +43.0% in previous quarter and historical rate -3.9%)
- Net Income -26.6% YoY (vs +609.7% in previous quarter and historical rate +17.2%)
- Net Income margin 28.3% decreased compared to 34.6% same period last year
- P/E multiple is 11.7x compared to historical level (75th percentile) of 11.3x
- P/S multiple is 3.2x
- Price to book: 2.1x

The company showed EPS +$6.86 per share. At the opening of the session the share price went up +3.2%

------------------------------------------------

2026-02-28

#reports #ADUS

[Addus HomeCare](https://eninvs.com/all.php?name=ADUS) (Social and medical services at home provider of ) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195445)
(2026-02-23, After Market Close):

- Revenue +35.1% YoY (vs +7.0% in previous quarter and historical rate +12.4%)
- EBITDA +73.5% YoY (vs +19.2% in previous quarter and historical rate +18.6%)
- EBITDA margin 15.8% increased compared to 12.3% same period last year
- Net Debt increased by $263 mln over the past reporting period (13.2% of market cap)
- FCF (LTM) +$0.3 bln (positive), 14.2% of market cap
- EV/EBITDA multiple is 14.1x compared to historical level (75th percentile) of 17.3x
- EV/Sales multiple is 1.7x

------------------------------------------------

2026-02-28

#reports #BRID

[Bridgford Foods Corporation](https://eninvs.com/all.php?name=BRID) (Packaged Foods) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195243)
(2026-01-19, After Market Close):

- Revenue +38.2% YoY (vs +180.0% in previous quarter and historical rate +18.9%)
- EBITDA -400% YoY (vs -60.0% in previous quarter)
- EBITDA margin -11.8% decreased compared to 5.5% same period last year
- Net Debt increased by $7 mln over the past reporting period (10.0% of market cap)
- FCF (LTM) -$0 bln (negative), 2.9% of market cap
- EV/Sales multiple is 0.2x

The company showed EPS -$1.47 per share

------------------------------------------------

2026-02-28

#reports #BDSX

[Biodesix](https://eninvs.com/all.php?name=BDSX) (Diagnostics and Research) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195237)
(2025-11-03, Before Market Open):

- Revenue +45% YoY (vs +22.2% in previous quarter and historical rate +32.7%)
- EBITDA margin -6.9% increased compared to -35.0% same period last year
- Net Debt decreased by $2 mln over the past reporting period (2.7% of market cap)
- FCF (LTM) -$0 bln (negative), 27.0% of market cap
- EV/Sales multiple is 1.4x

At the opening of the session the share price went down -1.0%

------------------------------------------------

2026-02-27

#reports #XRAY

[DENTSPLY SIRONA](https://eninvs.com/all.php?name=XRAY) (Dental materials and equipment manufacturer) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195211)
(2026-02-26, After Market Close):

- Revenue +49.4% YoY (vs -4.9% in previous quarter and historical rate +9.5%)
- EBITDA margin -3.5% increased compared to -23.4% same period last year
- Net Debt decreased by $55 mln over the past reporting period (2.0% of market cap)
- FCF (LTM) -$0.1 bln (negative), 2.3% of market cap
- EV/Sales multiple is 0.8x

------------------------------------------------

2026-02-27

#reports #XPOF

[Xponential Fitness, Inc.](https://eninvs.com/all.php?name=XPOF) (Leisure) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue 0% YoY (vs -1.2% in previous quarter and historical rate +10.1%)
- EBITDA margin -7.2% increased compared to -56.6% same period last year
- Net Debt increased by $125 mln over the past reporting period (45.8% of market cap)
- FCF (LTM) +$1.6 bln (positive), 582.7% of market cap
- EV/EBITDA multiple is 34.1x compared to historical level (75th percentile) of 67.1x
- EV/Sales multiple is 3.5x

------------------------------------------------

2026-02-27

#reports #WWW

[Wolverine World Wide](https://eninvs.com/all.php?name=WWW) (Clothing/shoes/accessories manufacturer) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue +4.6% YoY (vs +6.8% in previous quarter and historical rate -10.1%)
- EBITDA +19.6% YoY (vs +9.1% in previous quarter and historical rate +25.8%)
- EBITDA margin 10.6% increased compared to 9.3% same period last year
- Net Debt decreased by $132 mln over the past reporting period (9.2% of market cap)
- FCF (LTM) -$0 bln (negative), 2.3% of market cap
- EV/EBITDA multiple is 10.2x compared to historical level (75th percentile) of 15.3x
- EV/Sales multiple is 1.1x

------------------------------------------------

2026-02-27

#reports #WRBY

[Warby Parker Inc.](https://eninvs.com/all.php?name=WRBY) (Medical Instruments and Supplies) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue +11% YoY (vs +15.6% in previous quarter and historical rate +13.4%)
- EBITDA +71.4% YoY (vs +333.3% in previous quarter and historical rate +89.3%)
- EBITDA margin 5.7% increased compared to 3.7% same period last year
- Net Debt decreased by $5 mln over the past reporting period (0.1% of market cap)
- FCF (LTM) +$0 bln (positive), 0.6% of market cap
- EV/EBITDA multiple is 94.9x compared to historical level (75th percentile) of 202.8x
- EV/Sales multiple is 3.8x

------------------------------------------------

2026-02-27

#reports #VTRS

[Viatris](https://eninvs.com/all.php?name=VTRS) (Medicines manufacturer) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195208)
(2026-02-26, Before Market Open):

- Revenue +5% YoY (vs +0.2% in previous quarter and historical rate -4.1%)
- EBITDA -1% YoY (vs -20.9% in previous quarter and historical rate -20.6%)
- EBITDA margin 35.7% decreased compared to 37.9% same period last year
- Net Debt decreased by $372 mln over the past reporting period (2.3% of market cap)
- FCF (LTM) -$0 bln (negative), 0.2% of market cap
- EV/EBITDA multiple is 177.2x compared to historical level (75th percentile) of 15.1x
- EV/Sales multiple is 2x

------------------------------------------------

2026-02-27

#reports #VTEX

[VTEX](https://eninvs.com/all.php?name=VTEX) (Software — Application) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=6&id=230226)
(2026-02-26, After Market Close):

- Revenue +11.5% YoY (vs +9.8% in previous quarter and historical rate +22.0%)
- EBITDA margin 20.6% increased compared to -24.6% same period last year
- Net Debt decreased by $169 mln over the past reporting period (26.3% of market cap)
- FCF (LTM) -$0 bln (negative), 0.6% of market cap
- EV/EBITDA multiple is 23.9x compared to historical level (75th percentile) of 186.4x
- EV/Sales multiple is 1.9x

------------------------------------------------

2026-02-27

#reports #VCEL

[Vericel](https://eninvs.com/all.php?name=VCEL) (Medical services provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195207)
(2026-02-26, Before Market Open):

- Revenue +24% YoY (vs +17.2% in previous quarter and historical rate +18.7%)
- EBITDA +30% YoY (vs +500.0% in previous quarter)
- EBITDA margin 28.0% increased compared to 26.7% same period last year
- Net Debt decreased by $4 mln over the past reporting period (0.2% of market cap)
- FCF (LTM) +$0 bln (positive), 1.1% of market cap
- EV/EBITDA multiple is 92.8x compared to historical level (75th percentile) of 724.3x
- EV/Sales multiple is 6.7x

------------------------------------------------

2026-02-27

#reports #TTEC

[TTEC](https://eninvs.com/all.php?name=TTEC) (IT services provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195206)
(2026-02-26, After Market Close):

- Revenue +0.5% YoY (vs -1.9% in previous quarter and historical rate -4.2%)
- EBITDA -475% YoY (vs -7.9% in previous quarter and historical rate -26.3%)
- EBITDA margin -26.3% decreased compared to 7.1% same period last year
- Net Debt increased by $8 mln over the past reporting period (4.6% of market cap)
- FCF (LTM) +$0.1 bln (positive), 49.1% of market cap
- EV/Sales multiple is 0.5x

------------------------------------------------

2026-02-27

#reports #TRS

[TriMas](https://eninvs.com/all.php?name=TRS) (Engergy services provider) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue -32% YoY (vs +17.5% in previous quarter and historical rate +2.2%)
- EBITDA +85.2% YoY (vs +50.0% in previous quarter and historical rate +7.2%)
- EBITDA margin 32.3% increased compared to 11.8% same period last year
- Net Debt increased by $54 mln over the past reporting period (3.7% of market cap)
- FCF (LTM) -$0 bln (negative), 0.1% of market cap
- EV/EBITDA multiple is 13.3x compared to historical level (75th percentile) of 15.5x
- EV/Sales multiple is 2x

------------------------------------------------

2026-02-27

#reports #TKNO

[Alpha Teknova, Inc.](https://eninvs.com/all.php?name=TKNO) (Drug Manufacturers — Specialty and Generic) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue +11.1% YoY (vs 0.0% in previous quarter and historical rate -0.2%)
- EBITDA margin -50.0% increased compared to -66.7% same period last year
- EV/Sales multiple is 2.4x

------------------------------------------------

2026-02-27

#reports #TFX

[Teleflex](https://eninvs.com/all.php?name=TFX) (Medical equipment manufacturer) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue -28.4% YoY (vs +19.5% in previous quarter and historical rate +2.2%)
- EBITDA margin 4.9% increased compared to -11.1% same period last year
- Net Debt decreased by $80 mln over the past reporting period (1.7% of market cap)
- FCF (LTM) -$0.7 bln (negative), 15.1% of market cap
- EV/Sales multiple is 2.3x

------------------------------------------------

2026-02-27

#reports #STRA

[Strategic Education](https://eninvs.com/all.php?name=STRA) (Educational service provider) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue +3.9% YoY (vs +4.6% in previous quarter and historical rate +6.0%)
- EBITDA +89.4% YoY (vs +29.8% in previous quarter and historical rate +32.4%)
- EBITDA margin 27.6% increased compared to 15.1% same period last year
- Net Debt increased by $16 mln over the past reporting period (0.8% of market cap)
- FCF (LTM) +$0 bln (positive), 1.5% of market cap
- EV/EBITDA multiple is 7.1x compared to historical level (75th percentile) of 15x
- EV/Sales multiple is 1.5x

------------------------------------------------

2026-02-27

#reports #SNDX

[Syndax Pharmaceuticals](https://eninvs.com/all.php?name=SNDX) (Biotechnology) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195203)
(2026-02-26, After Market Close):

- Revenue +6700% YoY (vs +12600.0% in previous quarter and historical rate +50.0%)
- EBITDA margin -92.6% increased compared to -2700.0% same period last year
- Net Debt decreased by $1 mln over the past reporting period (0.1% of market cap)
- FCF (LTM) +$0.3 bln (positive), 25.6% of market cap
- EV/Sales multiple is 3.4x

------------------------------------------------

2026-02-27

#reports #SMP

[Standard Motor Products](https://eninvs.com/all.php?name=SMP) (Auto parts manufacturer) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195202)
(2026-02-26, Before Market Open):

- Revenue +342.6% YoY (vs +25.1% in previous quarter and historical rate +25.4%)
- EBITDA +661.5% YoY (vs +31.1% in previous quarter and historical rate +24.5%)
- EBITDA margin 6.5% increased compared to 3.8% same period last year
- Net Debt increased by $42 mln over the past reporting period (4.8% of market cap)
- FCF (LTM) +$0 bln (positive), 1.9% of market cap
- EV/EBITDA multiple is 6.2x compared to historical level (75th percentile) of 10.1x
- EV/Sales multiple is 0.5x

------------------------------------------------

2026-02-27

#reports #SJM

[JM Smucker](https://eninvs.com/all.php?name=SJM) (Food manufacturer) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195201)
(2026-02-26, Before Market Open):

- Revenue +7% YoY (vs +2.6% in previous quarter and historical rate +2.7%)
- EBITDA margin -17.3% increased compared to -21.6% same period last year
- Net Debt decreased by $449 mln over the past reporting period (4.1% of market cap)
- FCF (LTM) +$0 bln (positive), 0.4% of market cap
- EV/Sales multiple is 2.1x

------------------------------------------------

2026-02-27

#reports #SG

[Sweetgreen, Inc.](https://eninvs.com/all.php?name=SG) (Restaurants) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue -69.2% YoY (vs -6.3% in previous quarter and historical rate +34.2%)
- EBITDA margin -19.4% decreased compared to -4.6% same period last year
- Net Debt increased by $39 mln over the past reporting period (5.3% of market cap)
- FCF (LTM) -$0.1 bln (negative), 15.0% of market cap
- EV/Sales multiple is 1.2x

------------------------------------------------

2026-02-27

#reports #RYTM

[Rhythm Pharmaceuticals](https://eninvs.com/all.php?name=RYTM) (Molecular drug manufacturer) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue +35.7% YoY (vs +54.5% in previous quarter and historical rate +106.6%)
- EBITDA margin -68.4% increased compared to -78.6% same period last year
- Net Debt decreased by $16 mln over the past reporting period (0.2% of market cap)
- FCF (LTM) -$0 bln (negative), 0.3% of market cap
- EV/Sales multiple is 36.6x

------------------------------------------------

2026-02-27

#reports #ROCK

[Gibraltar Industries](https://eninvs.com/all.php?name=ROCK) (Engineering materials and metals supplier) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195195)
(2026-02-26, Before Market Open):

- Revenue -80.6% YoY (vs -13.9% in previous quarter and historical rate +6.5%)
- EBITDA -86.3% YoY (vs -7.8% in previous quarter and historical rate +13.0%)
- EBITDA margin 7.8% decreased compared to 11.0% same period last year
- Net Debt decreased by $29 mln over the past reporting period (1.9% of market cap)
- FCF (LTM) +$0.1 bln (positive), 4.1% of market cap
- EV/EBITDA multiple is 9.3x compared to historical level (75th percentile) of 11.9x
- EV/Sales multiple is 1.2x

------------------------------------------------

2026-02-27

#reports #REAL

[RealReal](https://eninvs.com/all.php?name=REAL) (Luxury Goods) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue +35.7% YoY (vs +11.3% in previous quarter and historical rate +12.4%)
- EBITDA margin 7.2% increased compared to -2.1% same period last year
- Net Debt increased by $31 mln over the past reporting period (1.7% of market cap)
- FCF (LTM) +$0 bln (positive), 0.4% of market cap
- EV/Sales multiple is 3.6x

------------------------------------------------

2026-02-27

#reports #PZZA

[Papa Johns International](https://eninvs.com/all.php?name=PZZA) (Owner of restaurants) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195193)
(2026-02-26, Before Market Open):

- Revenue -6.2% YoY (vs +0.2% in previous quarter and historical rate +9.6%)
- EBITDA +2.1% YoY (vs -72.3% in previous quarter and historical rate +20.4%)
- EBITDA margin 9.6% increased compared to 8.9% same period last year
- Net Debt decreased by $15 mln over the past reporting period (1.3% of market cap)
- FCF (LTM) +$0 bln (positive), 1.8% of market cap
- EV/EBITDA multiple is 13.5x compared to historical level (75th percentile) of 16.7x
- EV/Sales multiple is 1x

------------------------------------------------

2026-02-27

#reports #PUBM

[PubMatic, Inc.](https://eninvs.com/all.php?name=PUBM) (Software — Application) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue -7% YoY (vs -5.6% in previous quarter and historical rate +3.8%)
- EBITDA -13.3% YoY (vs -17.6% in previous quarter and historical rate +0.4%)
- EBITDA margin 65.0% decreased compared to 69.8% same period last year
- Net Debt decreased by $10 mln over the past reporting period (2.8% of market cap)
- FCF (LTM) +$0 bln (positive), 2.0% of market cap
- EV/EBITDA multiple is 4.3x compared to historical level (75th percentile) of 10.8x
- EV/Sales multiple is 0.9x

------------------------------------------------

2026-02-27

#reports #PSNL

[Personalis](https://eninvs.com/all.php?name=PSNL) (Diagnostics and Research) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195191)
(2026-02-26, After Market Close):

- Revenue 0% YoY (vs -46.2% in previous quarter and historical rate +5.1%)
- EBITDA margin -141.2% decreased compared to -100.0% same period last year
- Net Debt decreased by $90 mln over the past reporting period (9.4% of market cap)
- FCF (LTM) +$4.5 bln (positive), 473.0% of market cap
- EV/Sales multiple is 10.8x

------------------------------------------------

2026-02-27

#reports #PRVA

[Privia Health Group, Inc.](https://eninvs.com/all.php?name=PRVA) (Health Information Services) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue +17.4% YoY (vs +32.4% in previous quarter and historical rate +16.4%)
- EBITDA +111.1% YoY (vs +150.0% in previous quarter and historical rate +92.5%)
- EBITDA margin 3.5% increased compared to 2.0% same period last year
- Net Debt decreased by $35 mln over the past reporting period (1.2% of market cap)
- FCF (LTM) -$0.1 bln (negative), 1.9% of market cap
- EV/EBITDA multiple is 49.1x compared to historical level (75th percentile) of 102.9x
- EV/Sales multiple is 1.2x

------------------------------------------------

2026-02-27

#reports #PRGO

[Perrigo](https://eninvs.com/all.php?name=PRGO) (Drug Manufacturers — Specialty and Generic) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195190)
(2026-02-26, Before Market Open):

- Revenue -4.1% YoY (vs -3.2% in previous quarter and historical rate +1.9%)
- EBITDA -823% YoY (vs -57.1% in previous quarter and historical rate 0.0%)
- EBITDA margin -115.9% decreased compared to 15.4% same period last year
- Net Debt decreased by $218 mln over the past reporting period (11.3% of market cap)
- FCF (LTM) +$0.1 bln (positive), 7.5% of market cap
- EV/Sales multiple is 1.2x

------------------------------------------------

2026-02-27

#reports #PRAA

[PRA](https://eninvs.com/all.php?name=PRAA) (Financial services provider) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue +30.1% YoY (vs +32.6% in previous quarter and historical rate +8.0%)
- Net Income +391.7% YoY (vs +2200.0% in previous quarter and historical rate +30.6%)
- Net Income margin 17.7% increased compared to 4.7% same period last year
- P/E multiple is 4.6x compared to historical level (75th percentile) of 28.4x
- P/S multiple is 0.5x
- Price to book: 0.7x

------------------------------------------------

2026-02-27

#reports #PLTK

[Playtika Holding Corp.](https://eninvs.com/all.php?name=PLTK) (Electronic Gaming and Multimedia) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue +4.5% YoY (vs +8.7% in previous quarter and historical rate +1.9%)
- EBITDA -610.9% YoY (vs +0.8% in previous quarter and historical rate -26.5%)
- EBITDA margin -41.4% decreased compared to 8.5% same period last year
- Net Debt decreased by $187 mln over the past reporting period (12.8% of market cap)
- FCF (LTM) +$0 bln (positive), 2.2% of market cap
- EV/EBITDA multiple is 42.9x compared to historical level (75th percentile) of 8.9x
- EV/Sales multiple is 1.2x

------------------------------------------------

2026-02-27

#reports #PENN

[Penn National Gaming](https://eninvs.com/all.php?name=PENN) (Provider of entertainment services) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195188)
(2026-02-26, Before Market Open):

- Revenue +8.2% YoY (vs +4.8% in previous quarter and historical rate +3.1%)
- EBITDA +64.4% YoY (vs -476.1% in previous quarter and historical rate -13.7%)
- EBITDA margin 5.4% increased compared to 3.5% same period last year
- Net Debt increased by $84 mln over the past reporting period (3.9% of market cap)
- FCF (LTM) +$0 bln (positive), 1.1% of market cap
- EV/Sales multiple is 1.5x

------------------------------------------------

2026-02-27

#reports #PCRX

[Pacira BioSciences](https://eninvs.com/all.php?name=PCRX) (Medicines manufacturer) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195186)
(2026-02-26, After Market Close):

- Revenue +5.3% YoY (vs +6.5% in previous quarter and historical rate +3.0%)
- EBITDA -61.1% YoY (vs +1300.0% in previous quarter and historical rate +4.0%)
- EBITDA margin 7.1% decreased compared to 19.3% same period last year
- Net Debt decreased by $18 mln over the past reporting period (2.1% of market cap)
- FCF (LTM) +$0.1 bln (positive), 9.6% of market cap
- EV/EBITDA multiple is 17.4x compared to historical level (75th percentile) of 21.7x
- EV/Sales multiple is 1.6x

------------------------------------------------

2026-02-27

#reports #PAR

[PAR Technology Corporation](https://eninvs.com/all.php?name=PAR) (Restaurant software and hardware solutions provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195185)
(2026-02-26, After Market Close):

- Revenue +14.3% YoY (vs +22.7% in previous quarter and historical rate +9.9%)
- EBITDA margin -8.3% decreased compared to -7.6% same period last year
- Net Debt increased by $13 mln over the past reporting period (1.0% of market cap)
- FCF (LTM) -$0 bln (negative), 3.2% of market cap
- EV/Sales multiple is 3.5x

------------------------------------------------

2026-02-27

#reports #ORGO

[Organogenesis](https://eninvs.com/all.php?name=ORGO) (Drug Manufacturers — Specialty and Generic) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195183)
(2026-02-26, After Market Close):

- Revenue +78% YoY (vs +31.3% in previous quarter and historical rate +8.1%)
- EBITDA +378.6% YoY (vs +150.0% in previous quarter)
- EBITDA margin 29.6% increased compared to 11.0% same period last year
- Net Debt increased by $103 mln over the past reporting period (20.6% of market cap)
- FCF (LTM) -$0.1 bln (negative), 18.0% of market cap
- EV/EBITDA multiple is 20.4x compared to historical level (75th percentile) of 175.1x
- EV/Sales multiple is 2.2x

------------------------------------------------

2026-02-27

#reports #OPRA

[Opera](https://eninvs.com/all.php?name=OPRA) (Internet Content and Information) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue +53.9% YoY (vs +19.4% in previous quarter and historical rate +28.1%)
- EBITDA +37.5% YoY (vs +22.7% in previous quarter and historical rate +79.4%)
- EBITDA margin 18.6% decreased compared to 20.9% same period last year
- Net Debt decreased by $52 mln over the past reporting period (4.2% of market cap)
- FCF (LTM) +$0.1 bln (positive), 4.2% of market cap
- EV/EBITDA multiple is 10.1x compared to historical level (75th percentile) of 21.6x
- EV/Sales multiple is 2.1x

------------------------------------------------

2026-02-27

#reports #OPK

[OPKO Health](https://eninvs.com/all.php?name=OPK) (Diagnostics and Research) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195182)
(2026-02-26, After Market Close):

- Revenue -19.6% YoY (vs -12.6% in previous quarter and historical rate -13.7%)
- EBITDA margin -10.8% decreased compared to -7.1% same period last year
- Net Debt increased by $498 mln over the past reporting period (51.0% of market cap)
- FCF (LTM) +$0.6 bln (positive), 60.1% of market cap
- EV/Sales multiple is 2.3x

------------------------------------------------

2026-02-27

#reports #ONTF

[ON24, Inc.](https://eninvs.com/all.php?name=ONTF) (Software — Application) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue -5.4% YoY (vs -2.8% in previous quarter and historical rate -9.7%)
- EBITDA margin -8.6% increased compared to -18.9% same period last year
- Net Debt increased by $12 mln over the past reporting period (3.2% of market cap)
- FCF (LTM) +$0 bln (positive), 2.7% of market cap
- EV/Sales multiple is 1.5x

------------------------------------------------

2026-02-27

#reports #NVCR

[Novocure](https://eninvs.com/all.php?name=NVCR) (Medical services provider) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue +8.1% YoY (vs +7.7% in previous quarter and historical rate +7.3%)
- EBITDA margin -23.6% increased compared to -39.8% same period last year
- Net Debt increased by $25 mln over the past reporting period (1.8% of market cap)
- FCF (LTM) -$0 bln (negative), 3.5% of market cap
- EV/Sales multiple is 1.8x

------------------------------------------------

2026-02-27

#reports #NVAX

[Novavax](https://eninvs.com/all.php?name=NVAX) (Medicines manufacturer) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195180)
(2026-02-26, Before Market Open):

- Revenue -49.5% YoY (vs +286.4% in previous quarter and historical rate +29.1%)
- EBITDA margin 9.5% increased compared to -59.5% same period last year
- Net Debt decreased by $151 mln over the past reporting period (9.6% of market cap)
- FCF (LTM) +$0 bln (positive), 2.7% of market cap
- EV/Sales multiple is 1.4x

------------------------------------------------

2026-02-27

#reports #NTRA

[Natera](https://eninvs.com/all.php?name=NTRA) (Medical services provider) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue +39.9% YoY (vs +34.5% in previous quarter and historical rate +41.5%)
- EBITDA margin -3.5% increased compared to -13.7% same period last year
- Net Debt decreased by $42 mln over the past reporting period (0.2% of market cap)
- FCF (LTM) +$0.4 bln (positive), 1.5% of market cap
- EV/Sales multiple is 9.9x

------------------------------------------------

2026-02-27

#reports #NTAP

[NetApp](https://eninvs.com/all.php?name=NTAP) (Data storage services provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195178)
(2026-02-26, After Market Close):

- Revenue +6.7% YoY (vs +6.1% in previous quarter and historical rate +2.3%)
- EBITDA +0.8% YoY (vs +14.1% in previous quarter and historical rate +8.2%)
- EBITDA margin 28.1% decreased compared to 29.8% same period last year
- Net Debt decreased by $1.3 bln since the start of the year (6.0% of market cap)
- FCF (LTM) +$1.2 bln (positive), 5.5% of market cap
- EV/EBITDA multiple is 12x compared to historical level (75th percentile) of 15.4x
- EV/Sales multiple is 3.2x

------------------------------------------------

2026-02-27

#reports #MNST

[Monster Beverage](https://eninvs.com/all.php?name=MNST) (Energy drink supplier) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue +17.6% YoY (vs +16.8% in previous quarter and historical rate +9.7%)
- EBITDA +40.8% YoY (vs +37.2% in previous quarter and historical rate +16.4%)
- EBITDA margin 26.1% increased compared to 21.8% same period last year
- Net Debt increased by $188 mln over the past reporting period (0.2% of market cap)
- FCF (LTM) +$0.5 bln (positive), 0.6% of market cap
- EV/EBITDA multiple is 30.6x compared to historical level (75th percentile) of 28.2x
- EV/Sales multiple is 9.3x

------------------------------------------------

2026-02-27

#reports #MNKD

[MannKind Corporation](https://eninvs.com/all.php?name=MNKD) (Biotechnology) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195176)
(2026-02-26, Before Market Open):

- Revenue +45.5% YoY (vs +17.1% in previous quarter and historical rate +61.6%)
- EBITDA -117.2% YoY (vs +61.5% in previous quarter and historical rate +105.5%)
- EBITDA margin -4.5% decreased compared to 37.7% same period last year
- Net Debt increased by $334 mln over the past reporting period (23.7% of market cap)
- FCF (LTM) -$0 bln (negative), 0.7% of market cap
- EV/EBITDA multiple is 34.1x compared to historical level (75th percentile) of 32.4x
- EV/Sales multiple is 4.6x

------------------------------------------------

2026-02-27

#reports #MIDD

[Middleby](https://eninvs.com/all.php?name=MIDD) (Kitchen equipment manufacturer) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue -14.2% YoY (vs -3.9% in previous quarter and historical rate +5.6%)
- EBITDA -35.9% YoY (vs 0.0% in previous quarter and historical rate +2.0%)
- EBITDA margin 17.3% decreased compared to 23.2% same period last year
- Net Debt increased by $152 mln over the past reporting period (2.1% of market cap)
- FCF (LTM) +$0.5 bln (positive), 6.9% of market cap
- EV/EBITDA multiple is 12.5x compared to historical level (75th percentile) of 12x
- EV/Sales multiple is 2.5x

------------------------------------------------

2026-02-27

#reports #LNTH

[Lantheus](https://eninvs.com/all.php?name=LNTH) (Medicine equipment developer) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195175)
(2026-02-26, Before Market Open):

- Revenue +4.1% YoY (vs +1.3% in previous quarter and historical rate +19.4%)
- EBITDA -30.3% YoY (vs -56.8% in previous quarter and historical rate +26.9%)
- EBITDA margin 20.9% decreased compared to 31.2% same period last year
- Net Debt increased by $23 mln over the past reporting period (0.5% of market cap)
- FCF (LTM) -$0.6 bln (negative), 12.5% of market cap
- EV/EBITDA multiple is 12.3x compared to historical level (75th percentile) of 42.5x
- EV/Sales multiple is 3x

------------------------------------------------

2026-02-27

#reports #LNG

[Cheniere Energy](https://eninvs.com/all.php?name=LNG) (Oil and Gas Midstream) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue +22.9% YoY (vs +18.0% in previous quarter and historical rate -10.0%)
- EBITDA +120.6% YoY (vs +82.6% in previous quarter and historical rate +61.3%)
- EBITDA margin 82.9% increased compared to 46.1% same period last year
- Net Debt increased by $3.3 bln since the start of the year (6.2% of market cap)
- FCF (LTM) +$4.5 bln (positive), 8.6% of market cap
- EV/EBITDA multiple is 4.9x compared to historical level (75th percentile) of 8.7x
- EV/Sales multiple is 4x

------------------------------------------------

2026-02-27

#reports #LGND

[Ligand Pharmaceuticals](https://eninvs.com/all.php?name=LGND) (Medicines manufacturer) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue +39.5% YoY (vs +121.2% in previous quarter and historical rate +17.5%)
- EBITDA >1000% YoY (vs +1600.0% in previous quarter and historical rate +41.1%)
- EBITDA margin 41.7% increased compared to 4.7% same period last year
- Net Debt decreased by $75 mln over the past reporting period (2.2% of market cap)
- FCF (LTM) -$0 bln (negative), 1.1% of market cap
- EV/EBITDA multiple is 112.7x compared to historical level (75th percentile) of 315.6x
- EV/Sales multiple is 11.4x

------------------------------------------------

2026-02-27

#reports #LASR

[nLight](https://eninvs.com/all.php?name=LASR) (Semiconductor laser products manufacturer) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue +72.3% YoY (vs +19.6% in previous quarter and historical rate +4.7%)
- EBITDA margin -2.5% increased compared to -36.2% same period last year
- Net Debt decreased by $13 mln over the past reporting period (0.6% of market cap)
- FCF (LTM) -$0 bln (negative), 0.2% of market cap
- EV/Sales multiple is 7.9x

------------------------------------------------

2026-02-27

#reports #KIDS

[OrthoPediatrics](https://eninvs.com/all.php?name=KIDS) (Medical equipment developer) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue +17% YoY (vs +10.9% in previous quarter and historical rate +25.5%)
- EBITDA margin -4.8% increased compared to -18.9% same period last year
- Net Debt decreased by $3 mln over the past reporting period (0.7% of market cap)
- FCF (LTM) -$0 bln (negative), 9.1% of market cap
- EV/Sales multiple is 1.9x

------------------------------------------------

2026-02-27

#reports #KBR

[KBR](https://eninvs.com/all.php?name=KBR) (Engineering and construction and service company) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195172)
(2026-02-26, Before Market Open):

- Revenue -11.2% YoY (vs -0.8% in previous quarter and historical rate +6.3%)
- EBITDA +3.6% YoY (vs +9.3% in previous quarter and historical rate +38.5%)
- EBITDA margin 12.3% increased compared to 10.5% same period last year
- Net Debt increased by $26 mln over the past reporting period (0.4% of market cap)
- FCF (LTM) +$0.2 bln (positive), 2.7% of market cap
- EV/EBITDA multiple is 8.7x compared to historical level (75th percentile) of 17.4x
- EV/Sales multiple is 1.1x

------------------------------------------------

2026-02-27

#reports #INVA

[Innoviva](https://eninvs.com/all.php?name=INVA) (Biotechnology) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195171)
(2026-02-26, After Market Close):

- Revenue +25% YoY (vs +20.0% in previous quarter and historical rate +9.7%)
- EBITDA +44.8% YoY (vs +216.7% in previous quarter and historical rate +19.4%)
- EBITDA margin 36.5% increased compared to 31.5% same period last year
- Net Debt decreased by $73 mln over the past reporting period (5.5% of market cap)
- FCF (LTM) +$0.4 bln (positive), 27.8% of market cap
- EV/EBITDA multiple is 5.8x compared to historical level (75th percentile) of 8.2x
- EV/Sales multiple is 2.5x

------------------------------------------------

2026-02-27

#reports #INTU

[Intuit](https://eninvs.com/all.php?name=INTU) (Software developer) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195170)
(2026-02-26, After Market Close):

- Revenue +17.4% YoY (vs +18.3% in previous quarter and historical rate +14.4%)
- EBITDA +38.9% YoY (vs +83.5% in previous quarter and historical rate +24.2%)
- EBITDA margin 20.3% increased compared to 17.1% same period last year
- Net Debt increased by $495 mln over the past reporting period (0.3% of market cap)
- FCF (LTM) +$1 bln (positive), 0.6% of market cap
- EV/EBITDA multiple is 28.3x compared to historical level (75th percentile) of 46.9x
- EV/Sales multiple is 8x

------------------------------------------------

2026-02-27

#reports #ICFI

[ICF International](https://eninvs.com/all.php?name=ICFI) (Coach) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue -10.5% YoY (vs -10.1% in previous quarter and historical rate +2.1%)
- EBITDA -14% YoY (vs -10.2% in previous quarter and historical rate +8.5%)
- EBITDA margin 9.7% decreased compared to 10.1% same period last year
- Net Debt decreased by $54 mln over the past reporting period (3.1% of market cap)
- FCF (LTM) +$0 bln (positive), 0.9% of market cap
- EV/EBITDA multiple is 11.3x compared to historical level (75th percentile) of 18x
- EV/Sales multiple is 1.2x

------------------------------------------------

2026-02-27

#reports #HRTX

[Heron Therapeutics](https://eninvs.com/all.php?name=HRTX) (Medical services provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195167)
(2026-02-26, Before Market Open):

- Revenue +20.6% YoY (vs +35.5% in previous quarter and historical rate +21.7%)
- EBITDA margin 2.4% increased compared to -29.4% same period last year
- Net Debt decreased by $58 mln over the past reporting period (39.3% of market cap)
- FCF (LTM) -$0 bln (negative), 1.4% of market cap
- EV/Sales multiple is 1.6x

------------------------------------------------

2026-02-27

#reports #HRL

[Hormel Foods](https://eninvs.com/all.php?name=HRL) (Food products provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195166)
(2025-12-04, Before Market Open):

- Revenue +1.3% YoY (vs +1.5% in previous quarter and historical rate -0.6%)
- EBITDA +5.8% YoY (vs -79.9% in previous quarter and historical rate -6.8%)
- EBITDA margin 10.3% increased compared to 9.8% same period last year
- Net Debt decreased by $183 mln over the past reporting period (1.3% of market cap)
- FCF (LTM) +$0 bln (positive), 0.2% of market cap
- EV/EBITDA multiple is 13.1x compared to historical level (75th percentile) of 15.6x
- EV/Sales multiple is 1.3x

At the opening of the session the share price went up +7.9%

------------------------------------------------

2026-02-27

#reports #GOLF

[Acushnet](https://eninvs.com/all.php?name=GOLF) (Golf products supplier) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue +7.2% YoY (vs +6.0% in previous quarter and historical rate +4.1%)
- EBITDA margin -3.8% decreased compared to -1.1% same period last year
- Net Debt increased by $78 mln over the past reporting period (1.4% of market cap)
- FCF (LTM) -$0.1 bln (negative), 1.3% of market cap
- EV/EBITDA multiple is 20.2x compared to historical level (75th percentile) of 16.7x
- EV/Sales multiple is 2.5x

------------------------------------------------

2026-02-27

#reports #GLOB

[Globant](https://eninvs.com/all.php?name=GLOB) (IT services provider) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue +5.3% YoY (vs +12.8% in previous quarter and historical rate +23.4%)
- EBITDA -40% YoY (vs +1.6% in previous quarter and historical rate +32.1%)
- EBITDA margin 9.8% decreased compared to 17.2% same period last year
- Net Debt increased by $182 mln over the past reporting period (6.0% of market cap)
- FCF (LTM) -$0.1 bln (negative), 4.5% of market cap
- EV/EBITDA multiple is 10.8x compared to historical level (75th percentile) of 35.2x
- EV/Sales multiple is 1.4x

------------------------------------------------

2026-02-27

#reports #GIL

[Gildan Activewear](https://eninvs.com/all.php?name=GIL) (Apparel Manufacturing) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue +37.7% YoY (vs +3.2% in previous quarter and historical rate +7.2%)
- EBITDA -42.8% YoY (vs +26.4% in previous quarter and historical rate -2.9%)
- EBITDA margin 9.2% decreased compared to 22.1% same period last year
- Net Debt increased by $521 mln over the past reporting period (4.2% of market cap)
- FCF (LTM) +$0.2 bln (positive), 1.2% of market cap
- EV/EBITDA multiple is 22.4x compared to historical level (75th percentile) of 15.4x
- EV/Sales multiple is 4.1x

------------------------------------------------

2026-02-27

#reports #FOXF

[Fox Factory](https://eninvs.com/all.php?name=FOXF) (Shock absorber manufacturer) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue +8.4% YoY (vs +6.3% in previous quarter and historical rate +1.8%)
- EBITDA -1075.9% YoY (vs +107.7% in previous quarter and historical rate -22.0%)
- EBITDA margin -78.4% decreased compared to 8.7% same period last year
- Net Debt decreased by $15 mln over the past reporting period (1.9% of market cap)
- FCF (LTM) -$0.5 bln (negative), 66.8% of market cap
- EV/Sales multiple is 0.9x

------------------------------------------------

2026-02-27

#reports #FIGS

[FIGS, Inc.](https://eninvs.com/all.php?name=FIGS) (Apparel Manufacturing) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue +39.3% YoY (vs -1.4% in previous quarter and historical rate +21.7%)
- EBITDA +40% YoY (vs -181.8% in previous quarter and historical rate +1.7%)
- EBITDA margin 10.4% has not changed compared to 10.3% same period last year
- Net Debt decreased by $173 mln over the past reporting period (9.3% of market cap)
- FCF (LTM) +$0 bln (positive), 0.1% of market cap
- EV/EBITDA multiple is 77x compared to historical level (75th percentile) of 62.1x
- EV/Sales multiple is 3.3x

------------------------------------------------

2026-02-27

#reports #FCN

[FTI Consulting](https://eninvs.com/all.php?name=FCN) (Public relations agency) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195158)
(2026-02-26, Before Market Open):

- Revenue +10.7% YoY (vs +3.2% in previous quarter and historical rate +8.0%)
- EBITDA +65.6% YoY (vs +27.5% in previous quarter and historical rate +13.3%)
- EBITDA margin 10.7% increased compared to 7.2% same period last year
- Net Debt decreased by $264 mln over the past reporting period (4.1% of market cap)
- FCF (LTM) -$1 bln (negative), 15.5% of market cap
- EV/EBITDA multiple is 15.3x compared to historical level (75th percentile) of 18.8x
- EV/Sales multiple is 1.8x

------------------------------------------------

2026-02-27

#reports #FA

[First Advantage Corporation](https://eninvs.com/all.php?name=FA) (Specialty Business Services) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195157)
(2026-02-26, Before Market Open):

- Revenue +148.5% YoY (vs +51.2% in previous quarter and historical rate +16.2%)
- Net Income margin 0.7% increased compared to -1.8% same period last year
- P/S multiple is 2.2x
- Price to book: 1.6x

------------------------------------------------

2026-02-27

#reports #ESTC

[Elastic](https://eninvs.com/all.php?name=ESTC) (Information technology service provider) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue +17.8% YoY (vs +15.9% in previous quarter and historical rate +17.7%)
- EBITDA +45.5% YoY (vs -4.3% in previous quarter and historical rate +86.8%)
- EBITDA margin 7.1% increased compared to 5.8% same period last year
- Net Debt increased by $149 mln over the past reporting period (1.9% of market cap)
- FCF (LTM) -$0 bln (negative), 0.5% of market cap
- EV/EBITDA multiple is 81.8x compared to historical level (75th percentile) of 164.1x
- EV/Sales multiple is 4.3x

------------------------------------------------

2026-02-27

#reports #EME

[EMCOR Group](https://eninvs.com/all.php?name=EME) (Mechanical and electrical design services) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue +19.7% YoY (vs +16.4% in previous quarter and historical rate +15.3%)
- EBITDA +46.4% YoY (vs +9.4% in previous quarter and historical rate +39.7%)
- EBITDA margin 14.1% increased compared to 11.5% same period last year
- Net Debt decreased by $414 mln over the past reporting period (1.3% of market cap)
- FCF (LTM) -$0.8 bln (negative), 2.4% of market cap
- EV/EBITDA multiple is 17.2x compared to historical level (75th percentile) of 17.5x
- EV/Sales multiple is 1.8x

------------------------------------------------

2026-02-27

#reports #EBS

[Emergent BioSolutions](https://eninvs.com/all.php?name=EBS) (Medicines developer) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue -23.6% YoY (vs -21.4% in previous quarter and historical rate -7.5%)
- EBITDA -109.3% YoY (vs +53.8% in previous quarter and historical rate +39.2%)
- EBITDA margin -2.7% decreased compared to 22.1% same period last year
- Net Debt decreased by $51 mln over the past reporting period (8.5% of market cap)
- FCF (LTM) +$0.1 bln (positive), 16.5% of market cap
- EV/EBITDA multiple is 4.9x compared to historical level (75th percentile) of 100x
- EV/Sales multiple is 1.3x

------------------------------------------------

2026-02-27

#reports #DUOL

[Duolingo, Inc.](https://eninvs.com/all.php?name=DUOL) (Software — Application) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue +34.8% YoY (vs +40.9% in previous quarter and historical rate +42.7%)
- EBITDA +135% YoY (vs +162.5% in previous quarter and historical rate +118.0%)
- EBITDA margin 16.6% increased compared to 9.5% same period last year
- Net Debt decreased by $19 mln over the past reporting period (0.3% of market cap)
- FCF (LTM) +$0.2 bln (positive), 3.5% of market cap
- EV/EBITDA multiple is 31.9x compared to historical level (75th percentile) of 284.3x
- EV/Sales multiple is 4.7x

------------------------------------------------

2026-02-27

#reports #DH

[Definitive Healthcare Corp.](https://eninvs.com/all.php?name=DH) (Health Information Services) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195152)
(2026-02-26, After Market Close):

- Revenue 0% YoY (vs -4.8% in previous quarter and historical rate +3.2%)
- EBITDA margin -35.5% increased compared to -153.2% same period last year
- Net Debt decreased by $4 mln over the past reporting period (1.4% of market cap)
- FCF (LTM) +$0.1 bln (positive), 18.7% of market cap
- EV/Sales multiple is 1.5x

------------------------------------------------

2026-02-27

#reports #DELL

[Dell Technologies](https://eninvs.com/all.php?name=DELL) (IT services provider) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue -65.1% YoY (vs +10.8% in previous quarter and historical rate +11.7%)
- EBITDA +9.7% YoY (vs +223900.0% in previous quarter and historical rate +23.0%)
- EBITDA margin 31.5% increased compared to 10.0% same period last year
- Net Debt decreased by $1.7 bln since the start of the year (2.0% of market cap)
- FCF (LTM) +$8.8 bln (positive), 10.3% of market cap
- EV/EBITDA multiple is 6.7x compared to historical level (75th percentile) of 15.4x
- EV/Sales multiple is 0.9x

------------------------------------------------

2026-02-27

#reports #DCTH

[Delcath Systems](https://eninvs.com/all.php?name=DCTH) (Medical Devices) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195151)
(2026-02-26, Before Market Open):

- Revenue +40% YoY (vs +90.9% in previous quarter and historical rate +110.9%)
- EBITDA -250% YoY (vs -200.0% in previous quarter)
- EBITDA margin -14.3% decreased compared to 13.3% same period last year
- Net Debt decreased by $2 mln over the past reporting period (0.5% of market cap)
- FCF (LTM) +$0 bln (positive), 9.4% of market cap
- EV/EBITDA multiple is 147.3x compared to historical level (75th percentile) of 51x
- EV/Sales multiple is 3.4x

------------------------------------------------

2026-02-27

#reports #DCI

[Donaldson Company](https://eninvs.com/all.php?name=DCI) ( Filtration systems manufacturer) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195150)
(2026-02-26, Before Market Open):

- Revenue +5.9% YoY (vs +6.3% in previous quarter and historical rate +7.1%)
- EBITDA -4% YoY (vs +16.4% in previous quarter and historical rate +9.4%)
- EBITDA margin 16.0% decreased compared to 17.6% same period last year
- Net Debt increased by $182 mln over the past reporting period (1.5% of market cap)
- FCF (LTM) +$0.3 bln (positive), 2.2% of market cap
- EV/EBITDA multiple is 20.3x compared to historical level (75th percentile) of 15.5x
- EV/Sales multiple is 3.5x

------------------------------------------------

2026-02-27

#reports #CTKB

[Cytek Biosciences, Inc.](https://eninvs.com/all.php?name=CTKB) (Medical Devices) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195149)
(2026-02-26, After Market Close):

- Revenue +8.8% YoY (vs 0.0% in previous quarter and historical rate +7.7%)
- EBITDA -233.3% YoY (vs -800.0% in previous quarter)
- EBITDA margin -6.5% decreased compared to 5.3% same period last year
- Net Debt increased by $1 mln over the past reporting period (0.1% of market cap)
- FCF (LTM) -$0 bln (negative), 3.0% of market cap
- EV/Sales multiple is 2.2x

------------------------------------------------

2026-02-27

#reports #CSTL

[Castle Biosciences](https://eninvs.com/all.php?name=CSTL) (Cancer diseases) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue +1.2% YoY (vs -3.5% in previous quarter and historical rate +39.4%)
- EBITDA -100% YoY (vs -133.3% in previous quarter and historical rate +47.2%)
- Net Debt decreased by $32 mln over the past reporting period (2.5% of market cap)
- FCF (LTM) -$0 bln (negative), 3.6% of market cap
- EV/Sales multiple is 3.4x

------------------------------------------------

2026-02-27

#reports #CQP

[Cheniere Energy Partners](https://eninvs.com/all.php?name=CQP) (Oil and Gas Midstream) reported for 2025 q4
(2026-02-23, Before Market Open):

- Revenue +18.3% YoY (vs +17.0% in previous quarter and historical rate -8.9%)
- EBITDA +147.9% YoY (vs +97.8% in previous quarter and historical rate +67.8%)
- EBITDA margin 83.7% increased compared to 40.0% same period last year
- Net Debt decreased by $1 bln since the start of the year (3.7% of market cap)
- FCF (LTM) +$0.3 bln (positive), 1.1% of market cap
- EV/EBITDA multiple is 4.8x compared to historical level (75th percentile) of 9.6x
- EV/Sales multiple is 3.9x

------------------------------------------------

2026-02-27

#reports #CPNG

[Coupang, Inc.](https://eninvs.com/all.php?name=CPNG) (Internet Retail) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195143)
(2026-02-26, After Market Close):

- Revenue +301.6% YoY (vs +17.8% in previous quarter and historical rate +34.6%)
- EBITDA +52.8% YoY (vs +104.1% in previous quarter and historical rate +88.3%)
- EBITDA margin 2.1% decreased compared to 5.4% same period last year
- Net Debt increased by $301.9 bln since the start of the year (875.3% of market cap)
- FCF (LTM) +$301.5 bln (positive), 874.2% of market cap
- EV/EBITDA multiple is 190.5x compared to historical level (75th percentile) of 70.9x
- EV/Sales multiple is 5.8x

------------------------------------------------

2026-02-27

#reports #COMP

[Compass, Inc.](https://eninvs.com/all.php?name=COMP) (Software — Application) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue +4.9% YoY (vs +23.6% in previous quarter and historical rate +5.9%)
- EBITDA margin 6.7% increased compared to -1.5% same period last year
- Net Debt increased by $2.4 bln since the start of the year (42.2% of market cap)
- FCF (LTM) -$0 bln (negative), 0.7% of market cap
- EV/EBITDA multiple is 53.2x compared to historical level (75th percentile) of 217.5x
- EV/Sales multiple is 1.3x

------------------------------------------------

2026-02-27

#reports #CODI

[Compass Diversified](https://eninvs.com/all.php?name=CODI) (Conglomerates) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue -78.8% YoY (vs -18.9% in previous quarter and historical rate +6.5%)
- EBITDA -62.5% YoY (vs -111.3% in previous quarter and historical rate +8.4%)
- EBITDA margin 14.7% increased compared to 8.3% same period last year
- Net Debt increased by $123 mln over the past reporting period (26.0% of market cap)
- FCF (LTM) +$0.5 bln (positive), 108.8% of market cap
- EV/EBITDA multiple is 71x compared to historical level (75th percentile) of 16.5x
- EV/Sales multiple is 1.3x

------------------------------------------------

2026-02-27

#reports #CERT

[Certara, Inc.](https://eninvs.com/all.php?name=CERT) (Health Information Services) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195141)
(2026-02-26, After Market Close):

- Revenue -71.4% YoY (vs +10.5% in previous quarter and historical rate +16.9%)
- EBITDA margin 20.2% increased compared to -11.5% same period last year
- Net Debt decreased by $18 mln over the past reporting period (1.1% of market cap)
- FCF (LTM) -$0 bln (negative), 0.2% of market cap
- EV/EBITDA multiple is 17.4x compared to historical level (75th percentile) of 57.9x
- EV/Sales multiple is 4.1x

------------------------------------------------

2026-02-27

#reports #CELH

[Celsius](https://eninvs.com/all.php?name=CELH) (Food products provider) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue +108.1% YoY (vs -30.9% in previous quarter and historical rate +84.7%)
- EBITDA -56.7% YoY (vs -103.1% in previous quarter and historical rate +63.3%)
- EBITDA margin 3.6% decreased compared to 17.3% same period last year
- Net Debt increased by $2.1 bln since the start of the year (50.3% of market cap)
- FCF (LTM) +$0.1 bln (positive), 3.5% of market cap
- EV/EBITDA multiple is 30x compared to historical level (75th percentile) of 19.2x
- EV/Sales multiple is 3.6x

------------------------------------------------

2026-02-27

#reports #CARS

[Cars.com](https://eninvs.com/all.php?name=CARS) (A digital marketplace of cars) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195139)
(2026-02-26, Before Market Open):

- Revenue +2.2% YoY (vs +1.1% in previous quarter and historical rate +3.5%)
- EBITDA +7.7% YoY (vs -41.0% in previous quarter and historical rate -3.5%)
- EBITDA margin 15.2% increased compared to 14.4% same period last year
- Net Debt decreased by $1 mln over the past reporting period (0.1% of market cap)
- FCF (LTM) +$0 bln (positive), 4.1% of market cap
- EV/EBITDA multiple is 12.7x compared to historical level (75th percentile) of 15.1x
- EV/Sales multiple is 1.6x

------------------------------------------------

2026-02-27

#reports #BLD

[TopBuild](https://eninvs.com/all.php?name=BLD) (Building products provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195136)
(2026-02-26, Before Market Open):

- Revenue +13.2% YoY (vs +1.5% in previous quarter and historical rate +2.6%)
- EBITDA -7.1% YoY (vs -7.9% in previous quarter and historical rate +6.2%)
- EBITDA margin 15.8% decreased compared to 19.3% same period last year
- Net Debt increased by $1 bln since the start of the year (7.5% of market cap)
- FCF (LTM) -$0.6 bln (negative), 4.1% of market cap
- EV/EBITDA multiple is 17.3x compared to historical level (75th percentile) of 13.4x
- EV/Sales multiple is 3.1x

------------------------------------------------

2026-02-27

#reports #AUPH

[Aurinia Pharmaceuticals](https://eninvs.com/all.php?name=AUPH) (Drugs for autoimmune diseases developer) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue +71.1% YoY (vs +23.6% in previous quarter and historical rate +80.2%)
- EBITDA margin 42.9% increased compared to -126.7% same period last year
- Net Debt decreased by $374 mln over the past reporting period (19.3% of market cap)
- FCF (LTM) -$0 bln (negative), 2.1% of market cap
- EV/Sales multiple is 6.4x

------------------------------------------------

2026-02-27

#reports #ANIK

[Anika Therapeutics](https://eninvs.com/all.php?name=ANIK) (Pain medication manufacturer) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue 0% YoY (vs -28.2% in previous quarter and historical rate -8.7%)
- EBITDA margin 6.5% increased compared to -200.0% same period last year
- Net Debt increased by $2 mln over the past reporting period (1.5% of market cap)
- FCF (LTM) +$0 bln (positive), 5.3% of market cap
- EV/Sales multiple is 0.9x

------------------------------------------------

2026-02-27

#reports #AMWD

[American Woodmark](https://eninvs.com/all.php?name=AMWD) (Kitchen cabinets manufacturer ) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195130)
(2026-02-26, Before Market Open):

- Revenue -23.2% YoY (vs -4.6% in previous quarter and historical rate -2.1%)
- EBITDA -137.5% YoY (vs +21.4% in previous quarter and historical rate -12.9%)
- EBITDA margin -5.6% decreased compared to 11.4% same period last year
- Net Debt decreased by $10 mln over the past reporting period (1.2% of market cap)
- FCF (LTM) +$0 bln (positive), 2.3% of market cap
- EV/EBITDA multiple is 22.7x compared to historical level (75th percentile) of 13.8x
- EV/Sales multiple is 0.8x

------------------------------------------------

2026-02-27

#reports #AMPH

[Amphastar Pharmaceuticals](https://eninvs.com/all.php?name=AMPH) (Drug Manufacturers — Specialty and Generic) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195129)
(2026-02-26, After Market Close):

- Revenue -2.1% YoY (vs +0.5% in previous quarter and historical rate +14.1%)
- EBITDA -13.7% YoY (vs -47.6% in previous quarter and historical rate +18.8%)
- EBITDA margin 24.0% decreased compared to 27.3% same period last year
- Net Debt decreased by $8 mln over the past reporting period (0.6% of market cap)
- FCF (LTM) +$0 bln (positive), 3.9% of market cap
- EV/EBITDA multiple is 9.4x compared to historical level (75th percentile) of 14x
- EV/Sales multiple is 2.2x

------------------------------------------------

2026-02-27

#reports #AMBA

[Ambarella](https://eninvs.com/all.php?name=AMBA) (Semiconductor manufacturer) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue +20.2% YoY (vs +30.1% in previous quarter and historical rate +12.0%)
- EBITDA margin -13.9% increased compared to -25.0% same period last year
- Net Debt decreased by $18 mln over the past reporting period (0.6% of market cap)
- FCF (LTM) +$0 bln (positive), 0.8% of market cap
- EV/Sales multiple is 6.9x

------------------------------------------------

2026-02-27

#reports #ALHC

[Alignment Healthcare, Inc.](https://eninvs.com/all.php?name=ALHC) (Healthcare Plans) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue +117.8% YoY (vs +51.4% in previous quarter and historical rate +38.4%)
- Net Income margin -1.1% increased compared to -10.1% same period last year
- P/S multiple is 1.6x
- Price to book: 27.8x

------------------------------------------------

2026-02-27

#reports #AKBA

[Akebia Therapeutics](https://eninvs.com/all.php?name=AKBA) (Biotechnology) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195128)
(2026-02-26, Before Market Open):

- Revenue +26.1% YoY (vs +59.5% in previous quarter and historical rate +6.0%)
- EBITDA margin -8.6% increased compared to -23.9% same period last year
- Net Debt decreased by $18 mln over the past reporting period (5.8% of market cap)
- FCF (LTM) +$0.1 bln (positive), 36.8% of market cap
- EV/EBITDA multiple is 2.2x compared to historical level (75th percentile) of 56.6x
- EV/Sales multiple is 0.5x

------------------------------------------------

2026-02-27

#reports #AIRG

[Airgain](https://eninvs.com/all.php?name=AIRG) (Communication Equipment) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195127)
(2026-02-26, After Market Close):

- Revenue +20% YoY (vs +14.3% in previous quarter and historical rate 0.0%)
- EBITDA margin -16.7% increased compared to -50.0% same period last year
- Net Debt increased by $3 mln over the past reporting period (5.6% of market cap)
- EV/Sales multiple is 0.9x

------------------------------------------------

2026-02-27

#reports #AGO

[Assured Guaranty](https://eninvs.com/all.php?name=AGO) (Insurance — Specialty) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue -22.4% YoY (vs -1.3% in previous quarter and historical rate +20.8%)
- Net Income 0% YoY (vs +12.0% in previous quarter and historical rate +53.0%)
- Net Income margin 49.8% increased compared to 38.7% same period last year
- P/E multiple is 6.2x compared to historical level (75th percentile) of 9.2x
- P/S multiple is 5x
- Price to book: 1x

------------------------------------------------

2026-02-27

#reports #ADSK

[Autodesk](https://eninvs.com/all.php?name=ADSK) ( PC software and multimedia tools provider) reported for 2025 q4
(2026-02-26, After Market Close):

- Revenue +19.4% YoY (vs +18.0% in previous quarter and historical rate +12.9%)
- EBITDA +40.3% YoY (vs +19.3% in previous quarter and historical rate +13.9%)
- EBITDA margin 29.5% increased compared to 25.1% same period last year
- Net Debt decreased by $308 mln over the past reporting period (0.5% of market cap)
- FCF (LTM) +$0.2 bln (positive), 0.4% of market cap
- EV/EBITDA multiple is 35x compared to historical level (75th percentile) of 44.9x
- EV/Sales multiple is 8.4x

------------------------------------------------

2026-02-27

#reports #ACU

[Acme United Corporation](https://eninvs.com/all.php?name=ACU) (Household and Personal Products) reported for 2025 q4
(2026-02-26, Before Market Open):

- Revenue +4.3% YoY (vs +2.1% in previous quarter and historical rate +0.8%)
- EBITDA -99.9% YoY (vs -25.0% in previous quarter and historical rate +35.2%)
- EBITDA margin 6.3% decreased compared to 7591.3% same period last year
- Net Debt decreased by $5 mln over the past reporting period (3.4% of market cap)
- FCF (LTM) +$16.1 bln (positive), 10894.0% of market cap
- EV/EBITDA multiple is 6.8x compared to historical level (75th percentile) of 0x
- EV/Sales multiple is 0.8x

Switch to company model in classical logic    *